Background: Promising reports exist regarding the use of arsenic trioxide (ATO) as first-line treatment in acute promyelocytic leukemia (APL). Although the in vitro effect of ATO is extensively studied, the in vivo mechanism(s) of ATO action is mostly unknown.
introduction
Acute promyelocytic leukemia (APL) is a subtype of myeloid malignancies, which accounts for $10%-15% of acute myeloid leukemias. APL is characterized by reciprocal chromosomal translocation, t (15;17) , which results in PML-RARa fusion protein production and subsequent promyelocyte (PM) differentiation block. Complete remission (CR) is achieved by conventional antileukemic chemotherapy such as combination of anthracyclines and cytarabine in 60%-80% of patients. However, exacerbated bleeding causes increased frequency of early death [1] . All-trans retinoic acid (ATRA) has also been used for inducing remission in APL, which raised the CR rate to >90% with rapid improvement of hemorrhage. Despite excellent initial responses, APL cells develop resistance to ATRA, and relapse occurs in one-third of the patients following CR within 5 years [1] . Recently, arsenic compounds, mainly arsenic trioxide (ATO), have been used in the treatment of primary and relapsed APL patients.
The mechanism by which the therapeutic effect of ATO occurs is not completely elucidated. At the molecular level, ATO degrades PML-RARa and like ATRA, ATO at low concentrations induces PMs differentiation. At higher concentrations (>0.5 lM), ATO induces apoptosis in the abnormal PMs. ATO activity is shown to be accompanied by increased oxidant levels, disruption of mitochondrial membrane potential, release of cytochrome c, caspase activation, down-regulation of Bcl-2 and up-regulation of Bax proteins in the promyelocytic and other cell lines [2, 3] . The role of Bax in relation to the effects of ATO still remains controversial [4] [5] [6] . Bax is a proapoptotic member of the Bcl-2 family, which causes cytochrome c release from mitochondrial membrane and participates in caspase activation [7, 8] . Mitogen-activated protein kinases (MAPKs), including p38, ERK1/2 and c-Jun N-terminal kinases (JNK), are widely expressed serine-threonine kinases, mediating important regulatory signals in differentiation, proliferation and apoptosis [9] . The ERK1/2 and p38 pathways are of utmost importance in the regulation of cell differentiation, proliferation and original article apoptosis of APL cell lines [9] [10] [11] . In vitro studies have showed that MEK/ERK and p38 MAPK pathways have a positive role in the induction of differentiation of promyelocytic cell lines like NB4 and HL-60 by ATRA and ATO, respectively [10] [11] [12] [13] . Although the in vitro effect of ATO is widely investigated, the precise in vivo mechanisms through which ATO acts in APL have been briefly studied [14] . Therefore, evaluating the changes in molecular pathways and adverse effects resulting from ATO in APL patients could improve our understanding of the mechanisms involved in ATO therapy. The following study was carried out to evaluate the clinical efficacy and side-effects of ATO as induction therapy as well as changes in the expression of Bax, ERK, p38 and caspase-3 activity in PMs of patients with primary APL.
patients and methods patients Treatment and supportive care protocols for APL patients are described in our previous studies [15, 16] . In brief, 20 patients with newly diagnosed APL were involved and received induction therapy with ATO (Sina Darou, Tehran, Iran) from January 2006 to January 2007 at the dose of 0.15 mgÁkg/ day. The diagnosis of APL was established according to the clinical presentation and morphological criteria of the French-American-British classification and was confirmed by RT-PCR analysis for PML-RARa transcripts as described before [16] . Bone marrow (BM) aspirates were obtained during routine diagnostic assessment at days 14 and 28 of induction. Written informed consents were obtained from the patients after describing the study process in detail. The study was conducted according to the declaration of Helsinki and subsequent revisions and approved by local ethics committee at our university.
Twenty-eight days after completion of induction therapy, consolidation therapy was initiated and consisted of three outpatient infusions of ATO at an absolute dose of 10 mg/day. The consolidation was carried out 6 day/ week, for a total of 28 infusions. During this period, patients were visited every week by a hematologist. Complete blood count, liver aminotransferases level, renal function tests and electrocardiogram were assessed at each visit.
isolation of PMs from BM aspirates
At regular diagnostic protocol, 3-5 ml of BM aspirates were collected from seven patients at baseline and 14th and 28th days of induction therapy by ATO. Samples were placed into 15-ml tubes containing 2 ml anticoagulant citrate dextrose (25 mM sodium citrate and 126 mM glucose). Isolation of PM from BM was carried out according to the method described by Cowland and Borregaard [17] .
RNA isolation and RT-PCR
Total RNA was isolated from the peripheral leukocytes of the same patients from whom BM aspirates were obtained for PM isolation, at baseline and days 14 and 28 of ATO treatment using Trizol reagent (Invitrogen, Carlsbad, CA). The complementary DNA was synthesized using reverse transcriptase and sequence-specific primers were used for PML-RARa detection by RT-PCR according to the method described by Ghavamzadeh et al. [16] .
protein isolation and western blotting
The PMs isolated at baseline, 14th and 28th day of induction therapy, as described above, were resuspended in 100 ll lysis buffer (50 mM Hepes, pH 7.4; 5 mM 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate and 5 mM dithiothreitol) at 4°C for 15 min. Protein concentration was determined by Bradford assay. The samples were loaded (30 lg protein) onto sodium dodecyl sulfate-polyacrylamide gel and run at 120 V and 14 mA for 1.5 h. The gels were blotted on polyvinylidene fluoride membrane and the blots were incubated overnight at 4°C with polyclonal anti-Bax (1 : 2000), anti-p38 (1 : 1000), anti-ERK1/2 (1 : 1000) and anti-b-actin (1 : 1000) antibodies (all from Cell Signaling, Danvers, MA). Detection was carried out by BM Chemiluminescence Western Blotting Kit (Mouse/ Rabbit) (Roche, Mannheim, Germany) and secondary anti-gout and antirabbit antibody with the dilution of 1 : 10 000 from the same kit was applied for visualization on BioMax film (Kodak, Rochester, NY). The bands were digitized using Scion imaging V.4 (Scion Corp., Fredrick, MD) and normalized to b-actin bands.
caspase-3 activity assay
Activity of caspase-3 in 30 lg PMs lysate was assessed using Casp-3 kit (Sigma, St. Louis, MO) according to the manufacturer's guideline. The conditions of the assay were setup by using positive control cells treated with doxorubicin and negative controls treated with caspase-3-specific inhibitor.
statistical analysis
The data analysis was carried out using SPSS software (version 11.0). Data are presented as median of the findings and range. The percent changes in protein expressions are reported as mean 6 standard deviation. Nonparametric data were analyzed applying Mann-Whitney U test. Multiple comparisons were carried out using one-way analysis of variance followed by Tukey-Kramer post hoc analysis. P value <0.05 was considered as statistically significant. results patients Twenty patients with primary APL were involved. The study population consisted of 13 females (65%) and 7 males (35%) with the median age of 31 years (range: 15-62). RT-PCR analysis for PML-RARa fusion protein revealed that 10 patients had long isoform, while 4 other had short isoform. The type of isoform was not determined in the rest of the patients. The median and range of hemoglobin, white blood cell (WBC), red blood cell and platelet count of patients at baseline were 93 g/l (range: 40-142), 2.5 · 10 9 /l (range: 0.3-36.4), 3.2 · 10 9 /l (range: 1.5-4.9) and 47 · 10 9 /l (range: 12-100), respectively. Fibrinogen level, prothrombin time and partial thromboplastin time were 1.8 g/l (range: 0.9-4.1), 14.5 s (range: 12.0-22.6) and 31 s (range: 26-48), in that order.
treatment efficiency
The hematologic CR was observed in 85% (17 of 20 patients) of the study population. Two patients died early in the course of the induction therapy at days 4 and 6 because of respiratory distress following ATO-induced differentiation syndrome and hyperleukocytosis. Subsequently, ATO dose was reduced (5 mg/ day) in these patients and dexamethasone administration was started at 8 mg/day dosage, which was not effective. ATO therapy was interrupted in another patient because of acute renal insufficiency. In this patient, ATO therapy was displaced by chemotherapy (ATRA + idarubicin) to the end of induction period. CR was achieved in 17 patients with a median of 28 days (range: 18-36) to achieve BM blast clearance. The median total dose used for induction was 280 mg (range: 180-350).
Antigens and/or activities of some coagulation and fibrinolysis-related proteins were measured during ATO induction therapy. The results showed that fibrinogen degradation products, fibrinogen and platelet count returned to normal at the end of induction. Hemoglobin concentration also increased during the treatment despite an initial decrease early in the course of disease (Table 1) .
hyperleukocytosis
As shown in Figure 1A , the median peak time and leukocyte count were 15 days (range: 6-21) and 11.3 · 10 9 /l (range: 0.5-84.3), respectively. Twelve patients (63%) of 20 showed increased peripheral WBC count (cut-off point = 10 · 10 9 /l) with the baseline and peak median values of 3.4 · 10 9 /l (range: 1.2-26.4) and 24.5 · 10 9 /l (range: 10.4-70.5), respectively. The median period after ATO therapy for normal WBC count to be attained was 22 days (range: 8-28). Seven patients (37%) did not develop leukocytosis during treatment. The median baseline and peak level of leukocytes in these patients were 0.7 · 10 9 /l (range: 0.4-2.5) and 4.2 · 10 9 /l (range: 1.1-5.8), respectively ( Figure 1B) .
Comparing the APL differentiation syndrome (ADS) signs and symptoms in the patients with and without leukocytosis revealed that the incidence of fever, pleural effusion, weight gain, dyspnea and musculoskeletal pain was higher, but statistically not significant, in the presence of leukocytosis.
APL differentiation syndrome
ADS was observed in 12 patients (63%) with the median baseline and peak leukocyte count of 2.1 · 10 9 /l (range: 0.5-26.4) and 20.2 · 10 9 /l (range: 0.8-70.5), respectively. Seven APL patients (37%) did not develop the syndrome with the median baseline and peak leukocyte count of 1.2 · 10 9 /l (range: 0.4-5.6) and 4.9 · 10 9 /l (range: 1.1-72.6), respectively. There was significant difference between the peaks and not the baseline leukocyte counts in patients who developed ADS compared with patients without ADS (Mann-Whitney U test, P < 0.001 and P = 0.352, respectively) ( Figure 1C ). In patients with ADS, dexamethasone (8 mg/day) was initiated and ATO dosage was decreased to half. In one of the patients only ATO dosage reduction was carried out (Table 1) .
other adverse effects
As it is shown in Table 2 , the other side-effects of ATO therapy were liver transaminase elevation, respiratory problems such as dyspnea (75%, including any degree of respiratory discomfort) and pleural effusion (30%), night sweats (50%) and gastrointestinal upset such as nausea and vomiting. However, with the except of few cases of ADS and one case of renal insufficiency, the other adverse effects were nonlife threatening and tolerated by the patients and/or disappeared rapidly with symptomatic treatment. QT segment elongation was observed only in one patient.
PML-RARa transcript
Using a standard RT-PCR method with a sensitivity of 10 23 , three of nine patients who achieved CR were found to be negative for PML-RARa transcript after induction therapy.
Bax, p38 and ERK protein expression
To address the role of proteins involved in apoptosis and differentiation, the expression of Bax, p38 and ERK proteins (Figure 2 ). The expression of ERK was elevated by 149.9 6 24.3% and 190.8 6 29.2% (P < 0.05) at days 14 and 28, respectively. The change in Bax and p38 was $30% at day 14 (137.3 6 12.1%, P < 0.05 for Bax and 134.2 6 8.4%, P < 0.05 for p38). There was a greater increase in expression of Bax and p38 at day 28 reaching to 151.9 6 7.5% (P < 0.05) and 147 6 10% (P < 0.01), respectively.
caspase-3 activity
To study the effect of ATO on apoptosis induction, the activity of caspase-3 was assessed. The findings indicated that caspase-3 activity increased during the treatment in all patients except one. The overall caspase-3 activity has increased about five times at day 14 of induction and about two times at day 28 compared with the baseline.
discussion
Although experience with ATO therapy for APL patients is mostly limited to relapsed cases and controversial reports exist about the advantages of treatment with ATO alone or in combination with ATRA in APL [18] [19] [20] , a growing body of evidence points toward the effectiveness of ATO monotherapy as first-line treatment. Niu et al. [21] reported that CR was obtained in 8 of 11 (72.7%) newly diagnosed patients treated with ATO monotherapy (median time 35 days and median Annals of Oncology original article dose 295 mg). Comparably, Shen et al. [19] observed CR in 90% of APL patients in a median period of 31 days and accumulated dosage of 290 mg. Accordingly, Ravandi et al. [22] demonstrated that a regimen of ATRA plus ATO, with or without gemtuzumab, is safe and effective in patients with newly diagnosed APL. Our previous studies demonstrated that ATO, with or without ATRA, can yield CR rate of 86% in the newly diagnosed and relapsed APL patients [15, 16, 23] . In these studies, disease-free survival and overall survival for 2 years were 80% and 86%, respectively. Our current findings indicate CR in 85% of the patients in 28 days and accumulative dose of 280 mg, which are comparable with our previous report. Furthermore, we have found that the main adverse effects of ATO are ADS, gastrointestinal problems and liver enzymes elevation. In present study, 63% of patients developed AD symptoms; two of them had serious AD symptoms that led to ARDS and death. The WBC at diagnosis was high for these two patients (case 4, 12.6 · 10 9 /l and case 15, 10.2 · 10 9 /l); however, the baseline levels of leukocytes in patients with and without AD syndromes were not significantly different. In spite of small sample size, our data indicate the importance of leukocyte count at presentation and mortality of ATO treatment in APL. The signs and symptoms of AD symptoms like fever, dyspnea, pleural effusion, weight gain and musculoskeletal pain were more frequent in the patients with hyperleukocytosis. Our results confirm that a major concern about APL patients treated with ATO is early death secondary to hyperleukocytosis and ADS during induction therapy. Furthermore, patients who developed leukocytosis were more likely to develop the ADS. Current findings are in agreement with our previous report indicating that for early mortality, ADS during treatment and WBC count >10 · 10 9 /l are risk factors [23] . The syndrome successfully controlled in the most of these patients with dexamethasone (8 mg b.i.d. until the subside of signs) and decreasing the ATO dosage. ATO effects at the molecular level, like induction of differentiation and apoptosis, are mediated by PML-RARa degradation [24] [25] [26] . Considering the in vitro observations, we tested whether MAPK pathways are involved in the in vivo effects of ATO in APL patients. To the best of our knowledge, only one in vivo study of ATO mechanism in one APL patient, reporting an increase in the expression of caspase-1, -2 and -3 during the ATO therapy [14] , exists. The regulatory role of MAPKs in the differentiation, proliferation and apoptosis in Figure 2 . Expression of ERK1, Bax and p38 in the seven newly diagnosed acute promyelocytic leukemia (APL) patients during the induction therapy with arsenic trioxide (ATO). (A) Cell lysates were prepared from isolated promyelocyte (PM) cells from bone marrow of seven newly diagnosed APL patients (#3, #5, #6, #7, #9, #14 and #16) at days of 0, 14 and 28 of treatment as described in 'Patients and methods' section and 30 lg protein was subjected to 10% sodium dodecyl sulfate-polyacrylamide gel and transferred to polyvinylidene fluoride. The blots were incubated with anti-Bax, anti-p38 and anti-ERK1/2 antibodies and detected by chemiluminescence. The bands were visualized by chemiluminescence on BioMax film. (B) The expression of ERK1 (B), Bax (C) and p38 (D) in isolated PMs of APL patients during ATO treatment is presented. The bands from immunoblots were digitized using Scion imaging V.4 (Scion Corp) and normalized to b-actin band. The percentage of expression of proteins calculated to day 0 (before treatment) and presented as mean 6 standard deviation. Statistical analysis was carried out using one-way analysis of variance followed by Tukey-Kramer post hoc test (*P < 0.5 and **P < 0.01).
original article Annals of Oncology the hematologic malignancies and in the generation of ATOdependent effects has been previously reported [2, 9, 12, 13, 27] . The MEK/ERK and p38 pathways have a positive role in the induction of differentiation in APL cell lines like NB4 or HL-60 cells by ATRA and ATO [10] [11] [12] . We have demonstrated that ATO stimulates the expression of p38 and ERK1 proteins during the treatment. The expression was higher at day 14 of treatment and remained elevated at day 28 compared with the baseline. Whereas ERK activation has generally been associated with cytoprotective effects, increased activity of ERK has also been shown to promote differentiation [10, [28] [29] [30] [31] . Besides, recent studies indicate that activations of JNK/p38 are also important for cell survival and differentiation in immune system [32, 33] . Therefore, the increased expression of ERK1 and p38 in our study can be interpreted as induction of apoptosis and/or differentiation. Moreover, in our study, increased leukocytosis at day 14 was accompanied by the elevation of ERK1 expression, indicating a proliferative effect. Later in the course of treatment (day 28), leukocytosis lowered down to basal level in the presence of high ERK1, which might indicate a differentiation effect.
In vitro studies have shown that Bax expression, a proapoptotic member of the Bcl-2 family, is induced by ATO, indicating an apoptotic role for ATO on the leukemic cell lines [5, 6] . Our findings indicate that ATO treatment induces Bax expression in PMs of patients who achieved CR. Therefore, Bax expression might point toward the sensitivity and responsiveness of patients to ATO. Furthermore, in all patients treated with ATO, caspase-3 activity was augmented at day 14 and decreased at the 28th day of treatment, indicating the activation of mitochondrial apoptosis pathway by ATO in APL cells. On the other hand, the pattern of leukocytosis is completely coincident with the activity of caspase-3 during the treatment period. Despite the pivotal role of caspases in apoptosis, studies implicate their involvement in nonapoptotic functions such as differentiation and proliferation [34, 35] . For example, Sordet et al. [35] reported that macrophage differentiation from normal monocytes and U937 cells are accompanied by the activation of several caspase proteins. Thus, the change in caspase activity following ATO treatment can be involved in differentiation and/or apoptosis that need further evaluations. 
